NCT03940703 2026-02-27
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
EMD Serono
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT02864992 2025-12-23
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
EMD Serono
Phase 2 Active not recruiting
NCT04739358 2023-10-18
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Criterium, Inc.
Phase 1/2 Terminated
NCT03492437 2023-08-07
Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate
Merck KGaA, Darmstadt, Germany
Phase 1 Completed